Reverse predictive analysis of Rhizoma Pinelliae and Rhizoma Coptidis on differential miRNA target genes in lung adenocarcinoma

• Published in: Medicine (Baltimore) 2023-02, Vol.102 (7), p.e32999-e32999
• Main Authors: Meng, Tianwei, Liu, Jiawen, Chang, Hong, Qie, Rui
• Format: Article
• Language: English
• Subjects: Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - genetics; Carcinoma, Non-Small-Cell Lung; Drugs, Chinese Herbal - pharmacology; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; MicroRNAs; Molecular Docking Simulation; Observational Study; Pinellia - chemistry
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000032999

To use bioinformatics and network analysis to reveal the mechanism of “Rhizoma Pinelliae-Rhizoma Coptidis” herb pair in the treatment of lung adenocarcinoma. The target and pathway of “Rhizoma Pinelliae-Rhizoma Coptidis” herb pair in the treatment of lung adenocarcinoma were explored by online databases and network analysis tools, and the potential biomarkers of “Rhizoma Pinelliae-Rhizoma Coptidis” herb pair in the treatment of lung adenocarcinoma were predicted in reverse. A total of 59 traditional Chinese medicine compounds and 510 drug targets were screened in this study. A total of 25 micro-RNAs and 15,323 disease targets were obtained through GEO2R software analysis. In the end, 294 therapeutic targets and 47 core targets were obtained. A total of 186 gene ontology enrichment assays were obtained, and core therapeutic targets play multiple roles in biological processes, molecular functions, and cellular composition. Kyoto encyclopedia of genes and genomes pathway enrichment analysis showed that the core targets were mainly enriched in cancer-related pathways, immune-related pathways, endocrine-related pathways, etc, among which the non-small cell lung cancer pathway was the most significant core pathway. Molecular docking shows that the compound and the target have good binding ability. “Rhizoma Pinelliae-Rhizoma Coptidis” herb pair plays a mechanism of action in the treatment of lung adenocarcinoma through multiple targets and pathways. miR-5703, miR-3125, miR-652-5P, and miR-513c-5p may be new biomarkers for the treatment of lung adenocarcinoma.